Sanofi is still set on taking its multiple sclerosis (MS) med tolebrutinib to the FDA, executives have told Fierce Biotech, ...

Let's dive into a conversation with Ayla Ellison, Fierce Biotech Editor-in-Chief and Michelle Benz as they discuss the ...

The full picture of how Bayer's factor XIa inhibitor asundexian showed "inferior efficacy" compared to Eliquis has come into ...

A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a ...

Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million ...

The FDA has approved a new type of stent designed specifically for infants and young children—including neonates born with ...

The FDA’s Center for Drug Evaluation and Research (CDER) is consolidating its artificial-intelligence-related activities ...

Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores. | The TruSight Oncology ...

ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. | ReNeuron has joined the long list of ...

The Roche subsidiary will lay off 93 employees in South San Francisco starting in early October, according to a Worker ...

Medtech startups fared well in the second quarter with investment activity on track to surpass last year and ventu | ...

Earlier this month, Lykos was hit by an FDA rejection, research paper retractions and layoffs. Now, the FDA is looking into ...